Deep percutaneous penetration into muscles and joints

Journal of Pharmaceutical Sciences

Volumn 95, Issue 7, 2006, Pages 1405-1413

  Lee, Christine M ^a   Maibach, Howard I ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Diclofenac; Joints; Muscle; Percutaneous penetration; Pharmacokinetic models; Salicylic acid

Indexed keywords

DICLOFENAC; FELBINAC; FLURBIPROFEN; INDOMETACIN; KETOPROFEN; NAPROXEN; NONSTEROID ANTIINFLAMMATORY AGENT; PHENAZONE; PHENYLEPHRINE; PIROXICAM; SALICYLIC ACID DERIVATIVE; SALICYLIC ACID METHYL ESTER; TRIETHANOLAMINE SALICYLATE;

ABDOMINAL PAIN; ARTHROPATHY; CLINICAL TRIAL; DIARRHEA; DIGESTIVE SYSTEM PERFORATION; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DELIVERY SYSTEM; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MUSCLE LEVEL; DRUG PENETRATION; DYSPEPSIA; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL SYMPTOM; HUMAN; JOINT; KNEE OSTEOARTHRITIS; LIPOPHILICITY; MOLECULAR WEIGHT; MUSCLE; MUSCLE DISEASE; NONHUMAN; PHYSICAL CHEMISTRY; REVIEW; SKIN ABSORPTION;

EID: 33745888094     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.20666     Document Type: Article

References (26)

1. Ranade VV. 1991. Drug delivery systems. 6. Transdermal drug delivery. J Clin Pharmacol 31: 401-418.
2. Singh P, Roberts MS. 1994. Skin permeability and local tissue concentrations of nonsteroidal antiinflammatory drugs after topical application. J Pharmacol Exp Ther 268:144-151.
3. Yoshida D, Hasegawa T, Sugibayashi K. 2002. Targeting of salicylate to skin and muscle following topical injections in rats. Int J Pharm 231:177-184.
4. Guy RH, Maibach HI. 1983. Drug delivery to local subcutaneous structures following topical administration. J Pharm Sci 72:1375-1380.
5. Singh P. 1999. Percutaneous penetration as a method of delivery to skin and underlying tissues. In: Bronaugh RL, Maibach HI, editors. Percutaneous Absorption: Drugs-Cosmetics-Mechanisms-Methodology, vol. 97. New York: Marcel Dekker Inc., pp 597-613.
6. Cross SE, Anderson C, Thompson MJ, Roberts MS. 1997. Is there tissue penetration after application of topical salicylate formulations? Lancet 350:363.
7. Singh P, Roberts MS. 1994. Deep tissue penetration of bases and steroids after dermal application in rat. J Pharm Pharmacol 46:956-964.
8. Baldwin JR, Carrano RA, Imondi AR. 1984. Penetration of trolamine salicylate into the skeletal muscle of the pig. J Pharm Sci 73:1002-1004.
9. Megwa SA, Benson HAE, Roberts MS. 1995. Percutaneous absorption of salicylates from some commercially available topical products containing methyl salicylate or salicylate salts in rats. J Pharm Pharmacol 47:891-896.
10. Roberts MS, Anderson RA, Swarbrick J. 1977. Permeability of human epidermis to phenolic compounds. J Pharm Pharmacol 29:677-683.
11. Swarbrick J, Lee G, Brom J, Gensmantel N. 1984. Drug permeation through human skin: II. Permeability of ionizable compounds. J Pharm Sci 73:1352-1355.
12. Magnusson BM, Anissimov YG, Cross SE, Roberts MS. 2004. Molecular size as the main determinant of solute maximum flux across the skin. J Invest Dermatol 122:993-999.
13. Higaki K, Asai M, Suyama T, Nakayama K, Ogawara K, Kimura T. 2002. Estimation of intradermal disposition kinetics of drugs: II. Factors determining penetration of drugs from viable skin to muscular layer. Int J Pharm 239:129-141.
14. Yagi S, Nakayama K, Kurosaki Y, Higaki K, Kimura T. 1998. Factors determining drug residence in skin during transdermal absorption: Studies on beta-blocking agents. Biol Pharm Bull 21:1195-1201.
15. Singh P, Roberts MS. 1993. Dermal and underlying tissue pharmacokinetics of salicylic acid after topical application. J Pharmacokinet Biopharm 21:337-373.
16. Yanagimoto G, Hayashi T, Hasegawa T, Seki T, Juni K, Sugibayashi K, Morimoto Y. 1999. Skin disposition of drug after topical application in hairless rats. Chem Pharm Bull 47:749-754.
17. Radermacher J, Jentsch D, Scholl MA, Lustinetz T, Frolich JC. 1991. Diclofenac concentrations in synovial fluid and plasma after cutaneous application in inflammatory and degenerative joint disease. Br J Clin Pharmacol 31:527-541.
18. Muller M, Rastelli C, Ferri P, Jansen B, Breiteneder H, Eichler HG. 1998. Transdermal penetration of diclofenac after multiple epicutaneous administration. J Rheumatol 25:1833-1866.
19. Riess VW, Schmid K, Botta L, Kobayashi K, Moppert J, Schneider W, Sioufi A, Strusberg A, Tomasi M. 1986. Die perkutane Resorption von Diclofenav. Arzneim-Forsch/Drug Res 36:1092-1096.
20. Rabinowitz JL, Baker D. 1984. Absorption of labeled triethanolamine salicylate in human and canine knee joints. II. J Clin Pharmacol 24:532-539.
21. Guy RH, Hadgraft J, Maibach HI. 1982. A pharmacokinetic model for percutaneous absorption. Int J Pharm 11:119-129.
22. Barry B. 1988. Transdermal drug delivery. In: Aulton ME, editor. Pharmaceutics: the science of dosage form design. London: Harcourt Publishers Ltd., pp 499-533.
23. Higaki K, Nakayama K, Suyama T, Amnuaikit C, Ogawara K, Kimura T. 2004. Enhancement of topical delivery of drugs via direct penetration by reducing blood flow rate in skin. Int J Pharm 288: 227-233.
24. Singh P, Roberts MS. 1993. Iontophoretic transdermal delivery of salicylic acid and lidocaine to local subcutaneous structures. J Pharm Sci 82: 127-131.
25. Tugwell PS, Wells GA, Shainhouse JZ. 2004. Equivalence study of a topical diclofenac solution (Pennsaid®) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: A randomized controlled trial. J Rheumatol 31:2002-2012.
26. Suh H, Jun HW, Dzimianski MT, Lu GW. 1997. Pharmacokinetic and local tissue disposition studies of naproxen following topical and systemic administration in dogs and rats. Biopharm Drug Dispos 18:623-633.